Ignite Creation Date:
2024-05-06 @ 12:44 AM
Last Modification Date:
2024-10-26 @ 10:54 AM
Study NCT ID:
NCT01642966
Status:
COMPLETED
Last Update Posted:
2013-01-23
First Post:
2012-07-12
Brief Title:
Differential Effect of Ticagrelor Versus Prasugrel on the Adenosine-induced Coronary Vasodilatory Responses in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Sponsor:
University of Patras
Organization:
University of Patras
Study Overview
Official Title:
Differential Effect of Ticagrelor Versus Prasugrel on the Adenosine-induced Coronary Vasodilatory Responses in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a prospective randomized single-blind investigator-initiated crossover study Patients with Acute Coronary Syndrome ACS subjected to percutaneous coronary intervention PCI are randomized after informed consent in a 11 ratio to either ticagrelor 90mg x2 or prasugrel 10mg x1 for 15 days At Day 15 2 days coronary diastolic blood flow velocity in left anterior descending artery LAD is evaluated at baseline bCBFV and under 2 min adenosine infusions maximal diastolic CBFV- maxCBFV at gradually increasing doses of 50μgkgmin 80μgkgmin 110μgkgmin and 140μgkgmin with at least 5 min recovery intervals between infusions A crossover directly to the alternate treatment is performed followed by the same evaluation at Day 302 days
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None